Sign in
Long-term Clinical Impact of Intravitreal anti-VEGF Therapy for Severe Non-proliferative Diabetic Retinopathy (NPDR): Analyses Through a Discrete Event Simulation Model
Jennifer I. Lim, MD, FARVO, FASRS
Updates from the Field
2021
Continuous submicrogram fluocinolone acetonide (FAc) therapy for the treatment of diabetic retinopathy
Charles C Wykoff, MD, PhD, FASRS
2017
Abicipar Phase 2 MAPLE Trial Supports Improved Safety for Patients with nAMD Following a Modified Manufacturing Process
Raj K. Maturi, MD
2019
Category: Pharmacology